Printer Friendly

Keryx patents gene-based drug discovery involving kinase targeted compounds.

Keryx Biopharmaceuticals, Inc. (Jerusalem, Israel; 972 2541 2700) announced that the United States Patent and Trademark Office has granted patent 6,174,993, a critical patent related to drug discovery for an important family of kinases implicated in diseases such as cancer, diabetes, obesity, and autoimmune disorders. The new patent is owned jointly by Children's Hospital of Boston (Boston, MA) and The Hebrew University of Jerusalem (Jerusalem, Israel), and licensed exclusively to Keryx.

Kinases are essential for the body's intracellular signaling and other vital functions. The patent describes the recent discovery of a small area within a certain class of kinases that is highly specific to each% kinase. Details of this region are critical for the design of compounds that specifically target the kinase and form an essential part of Keryx's KinAce bioinformatics technology platform that utilizes sequence based genomics data for drug discovery.

Kinases, which play a key role in cell signaling, have emerged as one of the most promising classes of drug discovery targets for pharmaceutical and biotechnology companies. The technology of this patent , the first of several related to our core KinAce platform, provides a direct pathway from gene sequence data to potential drug candidates-an approach that we believe represents a new and extraordinarily efficient paradigm for drug discovery," said Morris Laster, MD, Chairman and Chief Executive Officer of Keryx "With the pending completion. of the draft of the human genome, the number of kinase targets is likely to increase."

"At Keryx, we have applied the technology of this patent and several pending applications to identify a number of promising early leads in hormone resistant prostate cancer, diabetes, obesity, fibrotic disorders, and autoimmune diseases," added Benjamin Corn, MD, President of Keryx . "In addition, the ability of our KinAce platform to rapidly generate specific kinase modulators provides a new and powerful tool for investigating kinase functional genomics."

Kinases are proteins that play a key role in the way cells communicate-a process known as signal transduction. If this communication is compromised, various disease states may result. Kinases regulate a variety of essential cellular events-such as the ability of cells to enter and/or complete mitosis (division), cellular proliferation, cellular differentiation, the control of fat metabolism, immune responses, inflammatory response and the control of glycogen metabolism. Therefore, compounds that have the ability to up and/or down regulate the activity of kinases have enormous potential for the treatment of many major diseases, such as cancer, obesity, autoimmune disorders, and diabetes. However, as kinases share very similar structures, identifying compounds that target specific kinases without interfering with the activity of others is a key challenge to kinase-based drug discovery.

The patent, which focuses on one of the most important classes of kinases called serine threonine kinases, is based on the discovery that short sequences (six to ten amino acids in length) derived from a specific region of serine threonine kinases sequences can be used to selectively modulate the activity of a kinase. The regions are distinct for each kinase, providing a basis for the discovery of highly specific modulators.

In addition to advancing its KinAce drug discovery technology, Keryx is developing KRX-101 (sulodexide), an in-licensed product that is in late stage clinical development for diabetic nephropathy. The company recently announced that it has secured a United States patent for the use of KRX-101 in the treatment of diabetic retinopathy, an eye-related complication of diabetes.

Keryx is building a pipeline of drug candidates that target protein kinases by applying its proprietary bioinformatics technology to genomics data. Kinases, which play a key role in the way cells communicate, are implicated in a wide range of diseases.
COPYRIGHT 2001 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Keryx patents gene-based drug discovery involving kinase targeted compounds.
Publication:BIOTECH Patent News
Geographic Code:7ISRA
Date:Feb 1, 2001
Words:603
Previous Article:Genvec expands its angiogenesis technoogy for the prevention of blindness.
Next Article:Patent issued to Infimed for its controlled release protein delivery technology.
Topics:


Related Articles
QBI RECEIVES MILESTONE PAYMENT FROM MITSUBISHI-TOKYO.
Kinetek acquires Tyrogene.
Vertex receives patent for drug discovery targeting kinase gene family.
Idun expands apoptosis patent portfolio.
Synaptic awarded patent for receptor linked to pain, blood pressure and other functions.
CYCLACEL REPORTS PROGRESS WITH 2ND GENERATION CDK INHIBITOR.
Cellular Genomics receives European patent for general methods for discovering enzyme inhibitors.
Aventis licenses Sertanty kinase structure activity database.
Corgentech licenses peptide delivery system from Cyclacel.
United States patent granted to Cyclacel for cyclin dependent kinase inhibitor series.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters